Expert Warns Of Looming 'Capacity Crunch' For New Cell And Gene Therapy Products
Executive Summary
Capacity shortages are looming for manufacturers wanting to develop and commercialize cell and gene therapy products over the next five years, an industry survey shows. The key finding: these firms should quickly build and staff the manufacturing facilities they will need.
You may also be interested in...
Interview: Measured Launch, Long Future For Gilead CAR-T In Europe
Positive recommendations for the approval of CAR-T therapies Yescarta and Kymriah were delivered in Europe in June. Michael Elliott, Gilead Sciences' VP for medical affairs in Europe, spoke to Scrip about the Yescarta launch strategy and the long-term future of CAR-T.
The Talent Challenge in Biologics Manufacturing
While companies are working hard to create new manufacturing capacity for biologics, protein production, which requires more highly trained and experienced workers, will remain constrained by a lack of qualified staff. Companies will need to act on a variety of fronts to deal with the problem--among them, more co-op hiring, and more partnering with companies with the requisite manufacturing capacity.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”